{"entity":{"id":"blossomhill-therapeutics","kind":"company","name":"BlossomHill Therapeutics","aka":[],"tldr":"BlossomHill Therapeutics designs pills against cancer mutations and pathways that current drugs miss: BH-30643 for EGFR-mutant lung cancer that has stopped responding, BH-30236 for acute myeloid leukaemia and higher-risk myelodysplastic syndromes, and a pan-KRAS drug heading for trials in 2027.","summary":"BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), headquartered at 10255 Science Center Drive, San Diego, was incorporated in Delaware in June 2020 and develops precision small-molecule cancer medicines. BH-30643 is a non-covalent inhibitor of mutant EGFR, described in trade coverage as macrocyclic,, including the C797S and T790M resistance mutations, in the phase 1/2 SOLARA study in EGFR-mutant non-small cell lung cancer, with a companion diagnostic planned for EGFR C797S-mutated disease. BH-30236 inhibits CLK kinases, which control alternative mRNA splicing, and is in phase 1 in relapsed or refractory acute myeloid leukaemia and higher-risk myelodysplastic syndromes. BH-501284 is a preclinical pan-KRAS inhibitor that spares HRAS and NRAS, with an IND planned for the first quarter of 2027. The company listed on the Nasdaq Global Select Market in August 2026, selling 9,375,000 shares at USD 16.00; its prospectus names Cormorant Asset Management, OrbiMed, Vivo Capital and Janus Henderson Investors as holders of 5 per cent or more.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.bhtherapeutics.com/"},{"label":"SEC EDGAR filings (CIK 0001839970)","url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001839970"},{"label":"Investor relations","url":"https://ir.bhtherapeutics.com/"},{"label":"SEC EDGAR: IPO prospectus (424B4), August 2026","url":"https://www.sec.gov/Archives/edgar/data/1839970/000119312526340215/d98958d424b4.htm"}],"tags":[],"related":[],"cancers":["egfr-mutant-nsclc","aml","mds-higher-risk","pancreatic","colorectal"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors","kras-inhibitors"],"targets":["egfr","kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Included as a company that went public in the window and was not in the corpus; it was founded in 2020, before the window. Facts are from the 424B4 prospectus (SEC CIK 0001839970) and the company website. Earlier private rounds (a USD 100 million Series B in 2024 and a USD 84 million Series B extension in 2025 appear in trade funding trackers) were not read on a primary source and are not recorded as rows. Trial registry numbers were not read. The older domain blossomhilltx.com is parked and is not the company's site."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.bhtherapeutics.com/","ticker":"BLSM","founded":2020,"stage":"public","investors":["cormorant-asset-management","orbimed"],"funding":[{"round":"IPO","year":2026,"amountUsd":150000000,"source":"https://www.sec.gov/Archives/edgar/data/1839970/000119312526340215/d98958d424b4.htm","note":"9,375,000 shares at USD 16.00 per share, prospectus dated 6 August 2026; base offering before underwriting discounts and any over-allotment"}]},"route":"/companies/blossomhill-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/"},{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/"}]}}